HIV vaccine vCP1433

Drug Profile

HIV vaccine vCP1433

Alternative Names: ALVAC-HIV vCP1433; vCP1433

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 31 Jul 2003 Phase-II clinical trials in HIV-1 infections in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top